Clinical trials increasingly focus on how medications perform across different demographics, including age groups, genetic backgrounds, and comorbidity profiles. Early-phase trials are primarily designed to evaluate safety signals and determine dosing ranges before larger efficacy studies begin. This is critical because phase I and early trials establish the foundational risk-benefit profile that determines whether a therapy advances to later stages.

Modern safety research also integrates predictive analytics and digital monitoring to detect adverse events earlier. New approaches such as AI-supported trial monitoring and protocol automation are improving data quality and reducing manual oversight, enabling more continuous safety evaluation during trials.